Advicenne
Signal active
Organization
Contact Information
Overview
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
About
Industries
Biotechnology, Pharmaceutical, Medical, Therapeutics
Founded
2007
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Advicenne headquartered in Europe, operates in the Biotechnology, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $6.1B in funding across 96 round(s). With a team of 11-50 employees, Advicenne is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Advicenne, raised $17.2M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
6
Investors
5
Lead Investors
0
Total Funding Amount
$63.4M
Details
1
Advicenne has raised a total of $63.4M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2017 | Private Equity | 17.2M |
Investors
Advicenne is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| IXO Private Equity | - | FUNDING ROUND - IXO Private Equity | 17.2M |
| Jean-Michel Petit | - | FUNDING ROUND - Jean-Michel Petit | 17.2M |
| Advicenne | - | FUNDING ROUND - Advicenne | 17.2M |
| IRDI | - | FUNDING ROUND - IRDI | 17.2M |
Recent Activity
There is no recent news or activity for this profile.